COMMD3-BMI1 readthrough protein (COMMD3-BMI1)

COMMD3-BMI1 readthrough protein is a fusion gene product resulting from naturally occurring readthrough transcription between the COMMD3 (COMM domain-containing protein 3) and BMI1 (Polycomb complex protein BMI-1) genes on chromosome 10[1][3][4]. The protein encompasses functional domains from both parent molecules, but its functional activity is primarily attributed to the BMI1 portion. BMI1 forms an essential part of the Polycomb repressive complex 1 (PRC1), regulating epigenetic gene silencing, chromatin compaction, and stem cell self-renewal by repressing cell cycle inhibitors (e.g., p16INK4a, p19Arf). Aberrant expression of BMI1, and by extension the readthrough fusion, plays a significant role in oncogenesis, cancer stemness, and therapy resistance. The fusion protein is thus a candidate therapeutic target in oncology, but no clinically approved drugs directly target the readthrough protein itself. Modulation of BMI1/PRC1 activity has raised interest in cancer therapy and regenerative medicine, but therapeutic inhibition may be associated with stem cell toxicity and impaired normal tissue regeneration[1][3][4].

Other names

BMI1PCGF4RNF51Polycomb complex protein BMI-1Polycomb group RING finger protein 4RING finger protein 51COMMD3-BMI1 read-through protein

Inhibition of Polycomb repressive complex 1 (PRC1) function (via BMI1 antagonists), leading to de-repression of tumor suppressor genes such as p16INK4a and p19Arf. Disruption of chromatin-mediated gene silencing.